(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Well informed: How to Take full advantage of Your Gadgets - 2New findings suggest atmosphere could exist on exoplanet TOI-561b
- 3US FDA approves Kura-Kyowa's blood cancer therapy
- 4If you want a true taste of Italian paradise, head to Favignana
- 5The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- 6 Popular Ladies' Aromas On the planet
- Artemis II crew take new photo of far side of the moon
- Nations for Rock Climbing
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- New Cheetos and Doritos will be free of artificial dyes
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Antimatter took to the road for the very first time. Here’s why it matters
